68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02174679 |
Expanded Access Status :
No longer available
First Posted : June 25, 2014
Last Update Posted : July 27, 2020
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Carcinoid Cancer Neuroendocrine Tumors Medullary Thyroid Cancer Cancers Expressing Somatostatin Receptors | Drug: 68Ga DOTATATE |
Study Type : | Expanded Access |
Official Title: | 68Ga-DOTATATE Imaging in Neuroendocrine Tumors |

- Drug: 68Ga DOTATATE
Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT.Other Name: 68Ga DOTATATE PET/CT Scan

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Older than 18 years the time of radiotracer administration
- Provides written informed consent
- Known diagnosis of NET or suspected SSTR positive tumors Women of childbearing age must have a negative pregnancy test at screening/baseline
- Able to remain still for duration of each imaging procedure (about 30 minutes)
Exclusion Criteria:
- Less than 18 years-old at the time of radiotracer administration
- Pregnant or nursing
- Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
- Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02174679
United States, California | |
UCLA Hospital | |
Los Angeles, California, United States, 90095 |
Principal Investigator: | Johannes Czernin, MD | University of California, Los Angeles |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Jonsson Comprehensive Cancer Center |
ClinicalTrials.gov Identifier: | NCT02174679 |
Other Study ID Numbers: |
DOTATATE12-001920EA NCI-2016-01796 ( Other Identifier: CTRP ) JCCCID324 ( Other Identifier: Jonsson Comprehensive Cancer Center ) |
First Posted: | June 25, 2014 Key Record Dates |
Last Update Posted: | July 27, 2020 |
Last Verified: | May 2019 |
Neuroendocrine Tumors Neoplasms Neuroectodermal Tumors |
Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Nerve Tissue |